Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aslamuzzaman Kazi

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Methods in Molecular Medicine|May 25, 2005
Cell cycle and drug sensitivityAslamuzzaman Kazi, Q Ping Dou
The Journal of Biological Chemistry|February 1, 2020
The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cellsHua Yang, Shengyan Xiang, Aslamuzzaman Kazi, et al.
Molecular Pharmacology|September 19, 2002
Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosisAslamuzzaman Kazi, David M Smith, Qing Zhong, et al.
Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2004
Isoflavones in breast cancer chemoprevention: where do we go from here?Nagi Kumar, Kathryn Allen, Diane Riccardi, et al.
Biochimica Et Biophysica Acta|May 26, 2004
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptorDeborah J Kuhn, Audrey C Burns, Aslamuzzaman Kazi, et al.
Current Cancer Drug Targets|November 25, 2005
Anti-angiogenic and anti-tumor properties of proteasome inhibitorsKenyon G Daniel, Deborah J Kuhn, Aslamuzzaman Kazi, et al.
Progress in Cell Cycle Research|November 5, 2003
Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapyQ Ping Dou, David M Smith, Kenyon G Daniel, et al.
Iscience|February 28, 2023
Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancersKatarzyna M Tyc, Aslamuzzaman Kazi, Alok Ranjan, et al.
The Journal of Biological Chemistry|February 27, 2014
Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activityAslamuzzaman Kazi, Sevil Ozcan, Awet Tecleab, et al.
British Journal of Haematology|October 6, 2025
Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma linesXiaoyan Hu, Lin Li, Jewel Nkwocha, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Methods in Molecular Medicine|May 25, 2005
Cell cycle and drug sensitivityAslamuzzaman Kazi, Q Ping Dou
The Journal of Biological Chemistry|February 1, 2020
The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cellsHua Yang, Shengyan Xiang, Aslamuzzaman Kazi, et al.
Molecular Pharmacology|September 19, 2002
Inhibition of bcl-x(l) phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosisAslamuzzaman Kazi, David M Smith, Qing Zhong, et al.
Frontiers in Bioscience : a Journal and Virtual Library|September 9, 2004
Isoflavones in breast cancer chemoprevention: where do we go from here?Nagi Kumar, Kathryn Allen, Diane Riccardi, et al.
Biochimica Et Biophysica Acta|May 26, 2004
Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptorDeborah J Kuhn, Audrey C Burns, Aslamuzzaman Kazi, et al.
Current Cancer Drug Targets|November 25, 2005
Anti-angiogenic and anti-tumor properties of proteasome inhibitorsKenyon G Daniel, Deborah J Kuhn, Aslamuzzaman Kazi, et al.
Progress in Cell Cycle Research|November 5, 2003
Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapyQ Ping Dou, David M Smith, Kenyon G Daniel, et al.
Iscience|February 28, 2023
Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancersKatarzyna M Tyc, Aslamuzzaman Kazi, Alok Ranjan, et al.
The Journal of Biological Chemistry|February 27, 2014
Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activityAslamuzzaman Kazi, Sevil Ozcan, Awet Tecleab, et al.
British Journal of Haematology|October 6, 2025
Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma linesXiaoyan Hu, Lin Li, Jewel Nkwocha, et al.
Pageof 5